Strategic partnerships Sanguine has a history of collaborations and partnerships, including a PV Reporter initiative and broad engagement with top pharma/biotech clients (35 of the top 40). This suggests opportunities to propose joint programs, co-sponsored studies, or expanded access to their biospecimen and real-world data capabilities for partner-driven translational research.

Expanded biospecimen portfolio Recent launches of Synovial Fluid and Skin Punch Biopsy collections, along with LeukoCert GMP leukopaks, indicate rapid portfolio growth. Target opportunities include clinical trial biomarker studies requiring diverse tissue types, as well as disease area expansion where these specimen types enable new biomarker discovery.

Global expansion Opened a new apheresis donor center in Los Angeles and ongoing facility expansion signals capacity growth and regional access. This supports sales pitches around faster sample collection, improved turnaround times, and scalable enrollments for multi-site studies across the U.S.

Financial health Revenue range of $50M-$100M with a recent $10M credit facility and overall funding of $12M suggests a financially solid but growth-minded partner. Approach opportunities could emphasize scalable pricing for larger biomarker programs, flexible financing for long-term studies, and value-based partnerships.

Clinical research impact Proven involvement with 35 of the top pharma/biotech companies and frequent reference in high-impact journals demonstrates credibility and proven outcomes. Leverage this track record to position Sanguine as a preferred data and biospecimen partner for late-stage translational research, biomarker validation programs, and cell & gene therapy studies.